D-AP7CAS# 81338-23-0 |
- Mc-MMAD
Catalog No.:BCC1735
CAS No.:1401963-15-2
- Monomethyl auristatin E
Catalog No.:BCC1775
CAS No.:474645-27-7
- CYT997 (Lexibulin)
Catalog No.:BCC4601
CAS No.:917111-44-5
- MPC 6827 hydrochloride
Catalog No.:BCC8040
CAS No.:917369-31-4
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 81338-23-0 | SDF | Download SDF |
| PubChem ID | 1617430 | Appearance | Powder |
| Formula | C7H16NO5P | M.Wt | 225.18 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in 1eq. NaOH | ||
| Chemical Name | (2R)-2-amino-7-phosphonoheptanoic acid | ||
| SMILES | C(CCC(C(=O)O)N)CCP(=O)(O)O | ||
| Standard InChIKey | MYDMWESTDPJANS-ZCFIWIBFSA-N | ||
| Standard InChI | InChI=1S/C7H16NO5P/c8-6(7(9)10)4-2-1-3-5-14(11,12)13/h6H,1-5,8H2,(H,9,10)(H2,11,12,13)/t6-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | More active form of AP7. DL Mixture also available. |
D-AP7 Dilution Calculator
D-AP7 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.4409 mL | 22.2045 mL | 44.4089 mL | 88.8178 mL | 111.0223 mL |
| 5 mM | 0.8882 mL | 4.4409 mL | 8.8818 mL | 17.7636 mL | 22.2045 mL |
| 10 mM | 0.4441 mL | 2.2204 mL | 4.4409 mL | 8.8818 mL | 11.1022 mL |
| 50 mM | 0.0888 mL | 0.4441 mL | 0.8882 mL | 1.7764 mL | 2.2204 mL |
| 100 mM | 0.0444 mL | 0.222 mL | 0.4441 mL | 0.8882 mL | 1.1102 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- ent-6,9-Dihydroxy-15-oxo-16-kauren-19-oic acid
Catalog No.:BCN1342
CAS No.:81264-00-8
- ent-6,9-Dihydroxy-15-oxo-16-kauren-19-oic acid beta-D-glucopyranosyl ester
Catalog No.:BCN1343
CAS No.:81263-98-1
- ent-6,11-Dihydroxy-15-oxo-16-kauren-19-oic acid beta-D-glucopyranosyl ester
Catalog No.:BCN1344
CAS No.:81263-97-0
- ent-9-Hydroxy-15-oxo-16-kauren-19-oic acid beta-D-glucopyranosyl ester
Catalog No.:BCN1345
CAS No.:81263-96-9
- 15-Deoxoeucosterol
Catalog No.:BCN4348
CAS No.:81241-53-4
- L-741,626
Catalog No.:BCC6886
CAS No.:81226-60-0
- Panaxynol
Catalog No.:BCN3833
CAS No.:81203-57-8
- Boc-D-Tyr(2-Br-Z)-OH
Catalog No.:BCC3464
CAS No.:81189-61-9
- Apatinib
Catalog No.:BCC5099
CAS No.:811803-05-1
- Imiloxan hydrochloride
Catalog No.:BCC6875
CAS No.:81167-22-8
- RR-src
Catalog No.:BCC6956
CAS No.:81156-93-6
- Pravastatin sodium
Catalog No.:BCC2321
CAS No.:81131-70-6
- Amisulpride hydrochloride
Catalog No.:BCC4252
CAS No.:81342-13-4
- Schisandrin C epoxide
Catalog No.:BCN3744
CAS No.:81345-36-0
- Cyclo(Tyr-Hpro)
Catalog No.:BCN2424
CAS No.:813461-21-1
- Momordicoside F1
Catalog No.:BCN3273
CAS No.:81348-81-4
- Momordicoside L
Catalog No.:BCN3274
CAS No.:81348-83-6
- Momordicoside K
Catalog No.:BCN3272
CAS No.:81348-84-7
- Momordicoside G
Catalog No.:BCN4349
CAS No.:81371-54-2
- Seglitide
Catalog No.:BCC7191
CAS No.:81377-02-8
- Fmoc-His(Boc)-OH.CHA
Catalog No.:BCC2595
CAS No.:81379-52-4
- Acetylvalerenolic acid
Catalog No.:BCC8112
CAS No.:81397-67-3
- Alfuzosin HCl
Catalog No.:BCC2494
CAS No.:81403-68-1
- Alfuzosin
Catalog No.:BCC4080
CAS No.:81403-80-7
Behavioral effects of D-AP7 in rats subjected to experimental hypoxia.[Pubmed:14506312]
Pol J Pharmacol. 2003 May-Jun;55(3):337-44.
We investigated the effects of D-AP7 [D-(-)-2-amino-7-phosphonoheptanoic acid], a specific, potent antagonist of NMDA receptor on certain forms of behavior in control groups of rats and in rats submitted to hypoxia. D-AP7 given intracerebroventrically (icv) at a dose of 5 nmol was tested in the open field test, passive avoidance test and in elevated plus maze test. D-AP7 did not significantly change the locomotor and exploratory activity, but it exhibited a tendency to enhance motility of rats in the open field test. It impaired the acquisition and did not influence the consolidation and retrieval in the passive avoidance situation. D-AP7 did not produce any significant effects in the elevated plus maze in rats which did not undergo hypoxia. Short-term hypoxia (about 3 min) decreased the crossings, rearings and bar approaches in the open field test and impaired acquisition, consolidation and retrieval processes. It did not evoke any changes in elevated plus maze. In hypoxia-treated groups of rats, D-AP7 enhanced locomotor and exploratory activity and it did not change the acquisition and retrieval processes. D-AP7 administrated before hypoxia impaired the consolidation in the passive avoidance test vs. D-AP7-treated group of rats. D-AP7 shortened the time spent in open arms and decreased the number of entries in open arms in hypoxia-treated groups of rats. In conclusion, in hypoxia-treated groups of rats, D-AP7 enhanced motility, exhibited anxiogenic-like effect and impaired consolidation in passive avoidance.
Cortically evoked excitatory synaptic transmission in the cat red nucleus is antagonised by D-AP5 but not by D-AP7.[Pubmed:1361408]
Brain Res. 1992 Oct 23;594(1):176-80.
Extracellular recordings were made from magnocellular red nucleus neurons (mRN) in alpha-chloralose (50 mg/kg, iv.) anaesthetised cats. Iontophoretically applied N-methyl-D-aspartate (NMDA) excited the neuronal firing which was antagonised by 4 selective NMDA receptor antagonists: 2-amino-5-phosphonopentanoate (AP5), 2-amino-7-phosphonoheptanoate (AP7), RS-4-(phosphonomethyl) piperazine-2-carboxylic acid (PMPC) and R-4-(3-phosphonopropyl) piperazine-2-carboxylic acid (CPP), whereas AMPA responses were uneffected. Monosynaptic excitatory responses were produced by stimulation of the sensorimotor cortex. These responses were reduced and often abolished by AP5 and PMPC but not by AP7 or CPP. It is postulated that two NMDA receptor subtypes exist on mRN neurones.
